Under the terms of the agreement, Intra-Cellular Therapies has regained all worldwide development and commercialization rights for the compounds previously licensed to Takeda. Takeda will be responsible for
The clinical-stage biotechnology company has obtained exclusive worldwide rights to use human insulin producing cells, termed "Melligen" cells, developed by University of Technology – Sydney’s (UTS) Professor Ann
Now through November 22, CVS/pharmacy customers will have the opportunity to support Stand Up To Cancer (SU2C) at the register in stores nationwide and online at www.cvs.com/SU2C. SU2C
The early termination of the HSR waiting period satisfies one of the conditions to the closing of the pending acquisition, which remains subject to other customary closing conditions.
AVP-825 is an investigational drug-device combination product developed by OptiNose which uses OptiNose’s patented Bi-Directional Breath Powered technology to deliver a low dose of sumatriptan powder into the
In addition, the USACC has contracted for clinical evaluation of the VesiculoVax Zaire-Ebola virus vaccine to meet the current outbreak in West Africa. The $9.5 million award has
A century later, it also is a symbol of environmental sustainability. Today, ZymoGenetics is among an elite group of laboratories around the world that have earned the U.S.
These waivers are applicable to current or pending New Drug Applications (NDAs) as well as successor products, including those with abuse-deterrent properties and associated labeling claims. In connection
This commitment from the Gates Foundation also includes additional investments in Affinivax based on the achievement of future success-based milestones. Proceeds from the funding will be used to
ASLAN’s adoption of the industry-leading Medidata Clinical Cloud™ supports the company’s strategy of maximizing the value of its in-licensed drug portfolio by conducting high quality, efficient clinical development
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.